Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-28T11:08:49Z | - |
dc.date.available | 2016-08-28T11:08:49Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 0390-6078 | * |
dc.identifier.other | OAK-18808 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/218284 | - |
dc.description.abstract | The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of >= 12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as >= 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse. | * |
dc.language | English | * |
dc.publisher | FERRATA STORTI FOUNDATION | * |
dc.title | Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 101 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 717 | * |
dc.relation.lastpage | 723 | * |
dc.relation.journaltitle | HAEMATOLOGICA | * |
dc.identifier.doi | 10.3324/haematol.2015.139899 | * |
dc.identifier.wosid | WOS:000379471900026 | * |
dc.identifier.scopusid | 2-s2.0-84971570003 | * |
dc.author.google | Lee, Sung-Eun | * |
dc.author.google | Choi, Soo Young | * |
dc.author.google | Song, Hye-Young | * |
dc.author.google | Kim, Soo-Hyun | * |
dc.author.google | Choi, Mi-Yeon | * |
dc.author.google | Park, Joon Seong | * |
dc.author.google | Kim, Hyeoung-Joon | * |
dc.author.google | Kim, Sung-Hyun | * |
dc.author.google | Zang, Dae Young | * |
dc.author.google | Oh, Sukjoong | * |
dc.author.google | Kim, Hawk | * |
dc.author.google | Do, Young Rok | * |
dc.author.google | Kwak, Jae-Yong | * |
dc.author.google | Kim, Jeong-A | * |
dc.author.google | Kim, Dae-Young | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Lee, Won Sik | * |
dc.author.google | Chang, Myung Hee | * |
dc.author.google | Park, Jinny | * |
dc.author.google | Kwon, Ji Hyun | * |
dc.author.google | Kim, Dong-Wook | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |